The Biotech anomaly
In the low-growth environment we are currently living in, one should expect that fast-growing sectors command a premium. However, what we have recently observed is a rush to low-growth, high-dividend stocks (so-called “bond proxies”) in a capitulation by investors crowded out of the bond market by central banks. These yield-starved investors have reluctantly bought the … Continued
